1 year return (CAGR)
24.31%
Basler Kantonalbank Exchange (SW, CHF)
BSKP.SW
98.70
+1.60 (+1.65%)
Financial ServicesBanks - Regional
Loading...
3 year return (CAGR)
15.78%
5 year return (CAGR)
9.60%
10 year return (CAGR)
3.77%
Objective Corporation Stock Analysis – State Within State
Read MoreMarketcap
503.34M
Price/Sales
0.19
Ent value
48.43B
Price/Book
0.11
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
100.09%
Trailing P/E
1.25
PEG
-
Forward P/E
-
EPS growth
-25.52%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 97.00 |
| Daily high | 98.70 |
| Daily low | 96.40 |
| Daily Volume | 4K |
| All-time high | 770.00 |
| 1y analyst estimate | - |
| Beta | 0.22 |
| EPS (TTM) | 9.88 |
| Dividend per share | 0.00 |
| Ex-div date | 27 Mar 2026 |
| Next earnings date | 25 Mar 2026 |
Downside potential
Loading...
Downside potential data
| BSKP.SW | S&P500 | |
| Current price drop from All-time high | -87.18% | -2.63% |
| Highest price drop | -92.39% | -56.47% |
| Date of highest drop | 29 Sep 2022 | 9 Mar 2009 |
| Avg drop from high | -75.62% | -10.68% |
| Avg time to new high | 37 days | 12 days |
| Max time to new high | 7082 days | 1805 days |
News
Investing.com -- European assets may offer investors advantages that are being overlooked as markets remain heavily focused on U.S. technology leadership, according to Macquarie Global Strategy, which...
September 20, 2026
Edison (BIT:EDNR) traded at €1.894 at the last close, with the share price lower over the past day, week, month, past 3 months and year to date. That recent slide in Edison’s share price adds to a wea...
September 19, 2026
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while a...
September 19, 2026
Novartis (SWX:NOVN) agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed...
September 19, 2026
WINNIPEG, MB / ACCESS Newswire / September 18, 2026 / (GSS-TSX.V)(GSR-Frankfurt/Freiverkehr & Xetra) (the "Company" or "Gossan") is pleased to announce that the Board of Directors has appointed Kevin ...
September 18, 2026
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
September 18, 2026
The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceutical therapies...
September 18, 2026
If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based o...
September 18, 2026
LPP Group reported Q2 net profit of 768m zlotys ($202.2m), up 64.5% YoY on a reported basis and 47.8% on a comparable basis adjusted for a prior-year Russia-related receivables write-off.
September 18, 2026
On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for...
September 18, 2026